Michael Szarek, PhD

home / authors / michael-szarek-phd

Articles

Michael Szarek, PhD, on Research Areas of Focus for Tivozanib in RCC

March 11th 2021

The expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.

Michael Szarek, PhD, on Treatment Advances With Tivozanib for RCC Going Forward

Michael Szarek, PhD

March 3rd 2021

The expert from SUNY Downstate Medical Center highlighted areas in which he believes treatment for renal cell carcinoma will advance.

Michael Szarek, PhD, on the Next Steps for Tivozanib in Patients with Advanced RCC

Michael Szarek, PhD

March 1st 2021

An analysis revealed that as a third- or fourth-line treatment for advanced renal cell carcinoma, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

Michael Szarek, PhD

February 27th 2021

An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.

Michael Szarek, PhD, on the Rationale Behind Conducting a Q-TWiST Analysis of the Phase 3 TIVO-3 Study

Michael Szarek, PhD

February 22nd 2021

A Q-TWiST analysis evaluated the use of tivozanib versus sorafenib among patients with advanced renal cell carcinoma included in the phase 3 TIVO-3 study.